Clinical Trials Directory

Trials / Sponsors / Trio Medicines Ltd.

Trio Medicines Ltd.

Industry · 14 registered clinical trials.

StatusTrialPhaseStarted
CompletedSelective β2-AR Antagonism in Asthma
Asthma
Phase 12018-02-28
CompletedYF476 in Barrett's Esophagus
Barrett's Esophagus
Phase 22013-05-15
TerminatedYF476 and Type I Gastric Carcinoids (Norway)
Chronic Atrophic Gastritis, Hypergastrinemia, Type I Gastric Carcinoids
Phase 22011-06-01
TerminatedYF476 and Type II Gastric Carcinoids
Zollinger-Ellison Syndrome
Phase 22011-04-11
CompletedYF476 and Type I Gastric Carcinoids
Chronic Atrophic Gastritis, Hypergastrinaemia, Type I Gastric Carcinoids
Phase 22011-01-04
CompletedEffect of Netazepide on Omeprazole-induced Changes in Chromogranin A and Gastrin
ECL-cell Hyperplasia, Parietal-cell Hyperplasia, Rebound Hyperacidity
Phase 12009-11-01
CompletedEffects of YF476 and Rabeprazole on Gastric Function
Hypergastrinaemia
Phase 12006-08-01
CompletedEffect of Single Doses of YF476 on Stomach Acidity
Hypergastrinaemia
Phase 12001-10-01
CompletedEffect of Repeated Doses of YF476 on Stomach Acidity
Hypergastrinaemia
Phase 12001-10-01
CompletedAvonex®: Safety, Blood Levels and Effects
Multiple Sclerosis (MS)
Phase 12001-01-01
CompletedEffect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers
Reflux Oesophagitis
Phase 11997-04-01
CompletedEffect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers
Reflux Oesophagitis
Phase 11996-08-01
CompletedEffect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed Stat
Reflux Oesophagitis
Phase 11996-07-01
CompletedSafety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Me
Reflux Oesophagitis
Phase 11996-05-01